Wider market obviously not helping. Some punting approval probably selling on the news, maybe early covering shorters gave it a bump? Aside from the SP today, the company is doing very well over the last 12-18 months IMO. Let's face it, the recent issues at OPT have put the emerging biotech space in a state of more uncertainty for now IMO. OCC capital management has been pretty good for a small biotech, their board was strengthened and they have had success across asia, Europe and now the US in the regulatory space. Without the current market issues, should be $1.70-$2 IMO so yes probably good secure buying during these times. GLTA
Ann: Investor Presentation - US FDA 510(k) Clearance for Remplir, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.035(2.60%) |
Mkt cap ! $320.6M | |||
| Open | High | Low | Value | Volume |
| $1.33 | $1.35 | $1.31 | $380.0K | 286.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9620 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7104 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| OCC (ASX) Chart |